Skip to content
Screener

Fulgent Genetics, Inc. FLGT Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Myriad Genetics logo
Myriad GeneticsMYGN
$673.7M-33.0%
Labcorp Holdings logo
Labcorp HoldingsLH
$18.53B+2.6%
Quest Diagnostics logo
Quest DiagnosticsDGX
$16.94B+6.1%
NeoGenomics logo
NeoGenomicsNEO
$1.35B-3.0%
Natera, Inc. logo
Natera, Inc.NTRA
$2.66B+51.2%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$526.64M-16.5%
Enterprise value$511.45M-6.7%
P/S1.6×-0.4×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 7:08 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-199065
Line itemMarch 31, 2026December 31, 2025
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding as of March 31, 2026, and December 31, 2025
Additional paid-in capital540,141574,520
Accumulated other comprehensive income4,5367,512
Retained earnings505,128529,954
Total Fulgent stockholders’ equity1,049,8091,111,989
Noncontrolling interest(5,655)(5,274)
Total stockholders’ equity1,044,1541,106,715
Total liabilities and stockholders’ equity$1,156,369$1,213,525

Item 1. Financial Statements.

FAQ

What is Fulgent Genetics, Inc.'s total liabilities & equity?
Fulgent Genetics, Inc. (FLGT) reported total liabilities & equity of $1.16B in Q1 2026.
How has Fulgent Genetics, Inc.'s total liabilities & equity changed year-over-year?
Fulgent Genetics, Inc.'s total liabilities & equity decreased by 4.1% year-over-year, from $1.21B to $1.16B.
What is the long-term trend for Fulgent Genetics, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Fulgent Genetics, Inc.'s total liabilities & equity has grown at a 11.6% compound annual growth rate (CAGR), from $700.46M to $1.21B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Fulgent Genetics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude